AR003919A1 - Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dicha - Google Patents
Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dichaInfo
- Publication number
- AR003919A1 AR003919A1 ARP960101095A AR10109596A AR003919A1 AR 003919 A1 AR003919 A1 AR 003919A1 AR P960101095 A ARP960101095 A AR P960101095A AR 10109596 A AR10109596 A AR 10109596A AR 003919 A1 AR003919 A1 AR 003919A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- accessory protein
- human
- interleukin
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Esta invención hace disponible por primera vez una proteína accesoria del receptor IL-1 humana que puede ser usado para regular los efectos de IL-1. Elagregado de esta proteina inhibe el efecto de IL-1 en las células.Por lo tanto, un aspecto de lainvención es proveer dicha proteína para el tratamiento decondiciones patológicas causadas por un exceso de actividad de las células que responden a IL-1 mediante el agregado de una cantidad de proteína accesoria delreceptor IL-1R humana (IL-1R AcP)suficiente para inhibir la activación de células por IL-1. Esta metodología también puede ser modificada, y la proteínaaccesoria puede ser usada como agente de rastreo para productos farmacéuticos. La invención comprende además el polinucleótido que codifica a dicha proteína,un vector, una célula huésped, una proteína de fusión que comprende dicha proteína, un anticuerpo que se une específicamente a dicha proteína, unacomposición farmacéutica que la comprende, un procedimiento parala preparación de dicha proteína y el empleo de dicha proteína como sustancia terapéutica parael tratamiento de respuestas inflamatorias o inmunológicas y/o para la regulación y prevención de las actividades inflamatorias o inmunológicas delainterleuquina-1, entre otras afecciones y/o enfermedades.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37626895A | 1995-01-23 | 1995-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR003919A1 true AR003919A1 (es) | 1998-09-30 |
Family
ID=23484321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960101095A AR003919A1 (es) | 1995-01-23 | 1996-01-19 | Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dicha |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0808365A1 (es) |
| JP (1) | JPH10512453A (es) |
| AR (1) | AR003919A1 (es) |
| AU (1) | AU4537096A (es) |
| BR (1) | BR9606837A (es) |
| CA (1) | CA2210724A1 (es) |
| CO (1) | CO4480033A1 (es) |
| CZ (1) | CZ208197A3 (es) |
| EA (1) | EA199700265A1 (es) |
| FI (1) | FI973089A0 (es) |
| HU (1) | HUP9702458A2 (es) |
| IL (1) | IL116796A0 (es) |
| MX (1) | MX9705501A (es) |
| NO (1) | NO973404D0 (es) |
| PE (1) | PE64396A1 (es) |
| PL (1) | PL321538A1 (es) |
| TR (1) | TR199700652T1 (es) |
| WO (1) | WO1996023067A1 (es) |
| ZA (1) | ZA96333B (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6974682B1 (en) | 1996-08-26 | 2005-12-13 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| AU7011696A (en) * | 1996-08-26 | 1998-03-19 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| AU736876B2 (en) | 1996-12-06 | 2001-08-02 | Amgen, Inc. | Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| AU741330B2 (en) * | 1997-04-30 | 2001-11-29 | F. Hoffmann-La Roche Ag | Rat ST38.2 chemokine |
| US6280955B1 (en) * | 1997-12-16 | 2001-08-28 | Tularik Inc. | Interleukin-1 receptor accessory proteins, nucleic acids and methods |
| AU755391B2 (en) | 1997-12-23 | 2002-12-12 | Immunex Corporation | SIGIRR DNA and polypeptides |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| US7049095B2 (en) | 2000-10-31 | 2006-05-23 | Immunex Corporation | DNA encoding IL-1 receptor accessory protein |
| GB2375604A (en) * | 2001-05-18 | 2002-11-20 | Warner Lambert Co | Methods for screening using interleukin soluble trimolecular complex |
| EP3492100B1 (en) | 2001-06-26 | 2021-12-08 | Amgen Inc. | Antibodies to opgl |
| KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| PL374118A1 (en) * | 2001-08-07 | 2005-10-03 | Immunex Corporation | Interleukin-1 receptors in the treatment of diseases |
| PL377091A1 (pl) | 2002-09-06 | 2006-01-23 | Amgen, Inc. | Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych |
| AU2005231822B2 (en) | 2004-04-02 | 2011-07-21 | Swedish Orphan Biovitrum Ab (Publ) | Methods of reducing aggregation of IL-1ra |
| US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| CA2607113C (en) * | 2004-05-05 | 2013-11-12 | Valorisation-Recherche, Societe En Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| US20090048161A1 (en) * | 2005-05-05 | 2009-02-19 | Valorisation Hsj, Societe En Commandite | Cytokine receptor modulators and uses thereof |
| US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| TW200736277A (en) | 2005-11-14 | 2007-10-01 | Amgen Inc | RANKL antibody-PTH/PTHrP chimeric molecules |
| WO2009120903A2 (en) | 2008-03-26 | 2009-10-01 | Cellerant Therapeutics, Inc. | Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof |
| EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| GB2472856B (en) * | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| JP5940093B2 (ja) | 2011-01-19 | 2016-06-29 | カンタージア アクチエボラーグ | 抗ｉｌ−１ｒａｐ抗体及びヒトを処置するためのそれらの使用 |
| RU2671980C2 (ru) | 2011-02-09 | 2018-11-08 | Натера, Инк. | Способы неинвазивного пренатального установления плоидности |
| EP2723365A1 (en) * | 2011-06-21 | 2014-04-30 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| GB201403875D0 (en) † | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| US20180173845A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| WO2016183106A1 (en) | 2015-05-11 | 2016-11-17 | Natera, Inc. | Methods and compositions for determining ploidy |
| EP3313887A2 (en) | 2015-06-26 | 2018-05-02 | MAB Discovery GmbH | Monoclonal anti-il-1racp antibodies |
| WO2017181202A2 (en) | 2016-04-15 | 2017-10-19 | Natera, Inc. | Methods for lung cancer detection |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| US10041044B2 (en) | 2016-07-29 | 2018-08-07 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
| GB201618485D0 (en) | 2016-11-02 | 2016-12-14 | Ucl Business Plc | Method of detecting tumour recurrence |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| US11773434B2 (en) | 2017-06-20 | 2023-10-03 | The Medical College Of Wisconsin, Inc. | Assessing transplant complication risk with total cell-free DNA |
| US12084720B2 (en) | 2017-12-14 | 2024-09-10 | Natera, Inc. | Assessing graft suitability for transplantation |
| JP7573443B2 (ja) | 2018-04-14 | 2024-10-25 | ナテラ， インコーポレイテッド | 循環腫瘍ｄｎａの個別化された検出を用いる癌検出およびモニタリングの方法 |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | 抗ｉｌ１ｒａｐ抗體及其使用方法 |
| US11931674B2 (en) | 2019-04-04 | 2024-03-19 | Natera, Inc. | Materials and methods for processing blood samples |
| WO2021236962A1 (en) | 2020-05-20 | 2021-11-25 | The Medical College Of Wisconsin, Inc. | Compositions and methods for inhibiting cytokine-release syndrome |
| US20240224961A1 (en) * | 2021-05-28 | 2024-07-11 | Biocytogen Jiangsu Co., Ltd. | Genetically modified non-human animal with human or chimeric il1rap |
| TW202428613A (zh) | 2022-09-21 | 2024-07-16 | 法商賽諾菲生物技術公司 | 人源化抗il-1r3抗體及使用方法 |
-
1996
- 1996-01-15 PE PE1996000031A patent/PE64396A1/es not_active Application Discontinuation
- 1996-01-16 ZA ZA96333A patent/ZA96333B/xx unknown
- 1996-01-17 CZ CZ972081A patent/CZ208197A3/cs unknown
- 1996-01-17 AU AU45370/96A patent/AU4537096A/en not_active Abandoned
- 1996-01-17 BR BR9606837A patent/BR9606837A/pt unknown
- 1996-01-17 JP JP8522598A patent/JPH10512453A/ja active Pending
- 1996-01-17 CA CA002210724A patent/CA2210724A1/en not_active Abandoned
- 1996-01-17 MX MX9705501A patent/MX9705501A/es unknown
- 1996-01-17 FI FI973089A patent/FI973089A0/fi unknown
- 1996-01-17 TR TR97/00652T patent/TR199700652T1/xx unknown
- 1996-01-17 EA EA199700265A patent/EA199700265A1/ru unknown
- 1996-01-17 WO PCT/EP1996/000181 patent/WO1996023067A1/en not_active Ceased
- 1996-01-17 EP EP96901291A patent/EP0808365A1/en not_active Withdrawn
- 1996-01-17 PL PL96321538A patent/PL321538A1/xx unknown
- 1996-01-17 HU HU9702458A patent/HUP9702458A2/hu unknown
- 1996-01-17 IL IL11679696A patent/IL116796A0/xx unknown
- 1996-01-19 AR ARP960101095A patent/AR003919A1/es unknown
- 1996-01-22 CO CO96002329A patent/CO4480033A1/es unknown
-
1997
- 1997-07-23 NO NO973404A patent/NO973404D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI973089A7 (fi) | 1997-07-22 |
| NO973404L (no) | 1997-07-23 |
| CA2210724A1 (en) | 1996-08-01 |
| IL116796A0 (en) | 1996-05-14 |
| EA199700265A1 (ru) | 1998-04-30 |
| WO1996023067A1 (en) | 1996-08-01 |
| NO973404D0 (no) | 1997-07-23 |
| MX9705501A (es) | 1997-10-31 |
| CZ208197A3 (en) | 1997-11-12 |
| PE64396A1 (es) | 1997-01-28 |
| BR9606837A (pt) | 1998-05-26 |
| CO4480033A1 (es) | 1997-07-09 |
| HUP9702458A2 (hu) | 1998-04-28 |
| EP0808365A1 (en) | 1997-11-26 |
| AU4537096A (en) | 1996-08-14 |
| FI973089L (fi) | 1997-07-22 |
| TR199700652T1 (xx) | 1998-02-21 |
| PL321538A1 (en) | 1997-12-08 |
| ZA96333B (en) | 1996-07-23 |
| FI973089A0 (fi) | 1997-07-22 |
| JPH10512453A (ja) | 1998-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR003919A1 (es) | Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dicha | |
| Vitaliano et al. | The relative importance of risk factors in nonmelanoma carcinoma | |
| Rosenthal et al. | Seasonal affective disorders | |
| Joling et al. | The cost-effectiveness of a family meetings intervention to prevent depression and anxiety in family caregivers of patients with dementia: a randomized trial | |
| BR0213846A (pt) | métodos de induzir seletivamente a apoptose nas células alvo que expressam dr5, de inibir a proliferação de células alvo que expressam dr5 e de tratar um paciente tendo uma doença inflamatória ou doença autoimune, e, composição | |
| EA200900272A1 (ru) | Комбинации для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом | |
| ES2194935T3 (es) | Preparados estables de transglutaminasa y procedimiento para su preparacion. | |
| AR100225A2 (es) | Anticuerpos anti-factor d humanizados y usos de los mismos | |
| RU2010108429A (ru) | Регуляторы ммр-9 и их применение | |
| Fagan | Remembering the lessons of basic pharmacology | |
| CY1109868T1 (el) | Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c | |
| GT200300294A (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso | |
| FR2819723B1 (fr) | Composition halogene, son procede de preparation et ses utilisations | |
| Abelaira et al. | Ketamine exhibits different neuroanatomical profile after mammalian target of rapamycin inhibition in the prefrontal cortex: the role of inflammation and oxidative stress | |
| BRPI0311511A8 (pt) | "preparações farmacêuticas líquidas, e sua aplicação". | |
| DE69422712D1 (de) | Tris-platin-komplexe | |
| ES2061521T3 (es) | Proteinas con actividad glutation-s-transferasa, secuencias de adn, anticuerpos, poxvirus y medicamentos para la prevencion de la equistosomiasis. | |
| ES2095216T3 (es) | Sistema transdermal con cesion escalonada del principio activo y su empleo para la administracion cosmetica local o sistemica del principio activo. | |
| Mazzara et al. | Atypical primary varicella rash: Systematic literature review | |
| Grimes et al. | Childhood vitiligo: clinical spectrum and therapeutic approaches | |
| ES2110057T3 (es) | Composicion medicinal que contiene tcf-ii. | |
| Bilgiç et al. | Possible atomoxetine-induced vitiligo: a case report | |
| Goldstein et al. | Combined use of benserazide and carbidopa in Parkinson's disease | |
| AR023464A1 (es) | Usos novedosos de la proteina ox2 de mamifero y reactivos relacionados | |
| Baliño et al. | Role of CA2+/calmodulin on ethanol neurobehavioral effects |